Capitalizing on New Opportunities for Stem Cell Products

As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Additionally, given that practical stem cell-based therapies can take years to develop, suppliers would benefit from a clear understanding of the wide range of products that support basic stem cell research already in progress.

Capitalizing on New Opportunities for Stem Cell Products, BioInformatics LLC' s latest report, will enable suppliers to respond quickly to a market disrupted by an Executive Order, and to gain a better understanding of how today' s stem cell products market is driven by long-term stem cell research requirements.

In Capitalizing on New Opportunities for Stem Cell Products, we surveyed close to 500 scientists from around the world about their current- and planned- areas of research, usage of stem cell products and preferred suppliers. This report will help you to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan long-term strategy to secure your leading position in this expanding market. For tactical planning purposes, the report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers. Combined with data on scientists' stem cell research budgets and expected changes in spending through 2011, suppliers can use this information to anticipate areas of growth and product saturation.

This analysis also provides suppliers with critical insight into optimizing product offerings based upon scientists' level of satisfaction with stem cell culture products and the level of interest in developing integrated stem cell product lines and services. The scientists surveyed share their opinions on what new product/technologies would be most beneficial to their research. Additionally, the report reveals what channels stem cell scientists use to access information relevant to their research, which in turn can be used by suppliers to more effectively target their products and services. The March 2009 policy change could have major implications for life science suppliers as academic scientists consider conducting research on previously unavailable embryonic stem cell lines. While the excitement about embryonic stem cell research is on the rise, including in the pharmaceutical and biotech industry, suppliers need actionable information about scientists' plans to pursue research using all types of cell lines in a global market. This report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic and induced pluripotent) and those likely to be used over the next several years- in addition to differentiated cell types and associated diseases under investigation- allowing suppliers to anticipate the types of stem cell culture products scientists will need to purchase. Moreover, this report includes a supplemental section about scientists who plan to conduct stem cell research in the near future to help companies better anticipate the stem cell product needs of new customers.

Capitalizing on New Opportunities for Stem Cell Products provides a roadmap for stem cell product suppliers to help navigate a landscape that is poised for change- and growth. This analysis was designed to guide suppliers in redirecting resources to new areas and markets, and to help refine current offerings by making them more responsive to scientists who are already engaged in stem cell research.

• Identify new/expanding stem cell research opportunities as a result of the ban on federal funding for research on human embryonic stem cells being lifted
• Estimate market share for stem cell research products
• Project growth of stem cell research products by market segment and geographic region
• Learn types and species of stem cells scientists intend to use
• Determine level of satisfaction with stem cell media and unmet needs with respect to stem cell products and cell lines
• Uncover interest in integrated stem cell workflow products and services

Since our inception in 1994, BioInformatics has provided critical market intelligence to leading companies serving the life science, medical device and pharmaceutical industries. We support clients across the entire market spectrum - from scientific research to diagnostics and therapeutics - providing high-level management with market insights from gene to drug.

Our multi-disciplinary team of scientific experts and business analysts creates value for our clients by combining extensive industry knowledge and experience. We offer a variety of products and services that enable executives to see themselves, their market and their competitors through the eyes of the most important information source of all - customers. We can precisely meet the needs of our clients through the most appropriate mix of research methodologies, including:

• Online Surveys
• Online Focus Groups
• Mail Surveys
• Telephone Interviews